Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of 18F-LNC1007 PET/CT in Healthy Volunteers and Cancer Patients
NCT06471712Phase 1Completed
- Sponsor
- Yantai Lannacheng Biotechnology Co., Ltd.
- Start
- Jul 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fibrostatin fluoride [18F] in cancer, sponsored by Yantai Lannacheng Biotechnology Co., Ltd. Primary endpoint: Safety of 18F-LNC1007 injection at 2 years. Started Jul 2024; status: completed.
02
Drugs
fibrostatin fluoride [18F]
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06471712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06471712.